Hey There : )
Unlisted Shares
Price Chart
1W
1M
1Y
MAX
High
-
Low
-
Return
-
Sigachi Laboratories Ltd Essentials
As of September 08, 2024, Sigachi Laboratories Ltd, Unlisted share price is ₹43.00 per share and the face value is ₹10.00/share. The lot size of Sigachi Laboratories Ltd is 4700 shares. The 52-week high for Sigachi Laboratories Ltd stock price is ₹47, while the 52-week low is ₹43
An International Securities Identification Number (ISIN) is a code that uniquely identifies a specific securities issue. The numbers are allocated by a country's respective national numbering agency (NNA).
Value of a security, as stated by its issuer. It has no relation with market price of the stock.
Total shares or total number of shares outstanding represents the amount of stock on the open market, including shares held by institutional investors and restricted shares held by insiders and company officers.
Gross income refers to the total income earned by an individual on a pay check before taxes and other deductions. It comprises all incomes received by an individual from all sources – including wages, rental income, interest income, and dividends.
It is the final profit left over after subtracting all operating and non operating items from net revenue.
It is the profit allocated to each outstanding share of common stock.
It is a valuation parameter that measures the company's current share price relative to its per-share earnings. Generally, high P/E is Overvalued & low P/E is Undervalued.
It shows the relationship between the current price and the book value of each share. A lower P/B ratio can mean that the stock is undervalued.
Market capitalization is the aggregate valuation of the company based on its current share price and the total number of outstanding shares.
It measures companys total value, which includes market capitalization, debt and excludes cash.
It calculates the per share value of a company based on its equity available to common shareholders
Intrinsic value is the anticipated value of a company or stock determined through fundamental analysis. It is also referred to as the price a rational investor is willing to pay for an investment, given its level of risk.
A sector is an area in which businesses share the same or a related product or service. It can also be known as an industry or market that shares common operating characteristics
Subsectors are the divisions of a sector. They are areas that vary from the rest of the sector substantially enough to justify creating a plan just for the subsector.
Category is defined as a class or division of things regarded as having particular shared characteristics.
It indicates the amount of money a company brings in from its ongoing and regular operations over a fixed period of time.
Average traded price is the average price at which a stock trades over a period of time.
Sigachi Laboratories Ltd Growth
Compounded Sales Growth
Compounded Profit Growth
Return On Equity
Highlights
- Bulk Drugs and Drug Intermediates - Sigachi Laboratories Limited functions as a pharmaceutical company, specialising in the manufacturing of bulk drugs and drug intermediates. However, it is worth noting that apart from the pharmaceuticals business, the company is also involved in channelling funds into equity and mutual funds. Its primary investment focus revolves around sectors such as pharmaceuticals, banking, and energy. As per the segmentation shared by the company, the company earns ~50% of revenue from both the segments.
- Revenue Growth - The company's revenue has marginally increased, climbing from ₹1.23 crore in FY22 to ₹1.29 crore in FY23, indicating a growth rate of 4.9%. Over the past five years, the company's revenue has increased at a slower pace, achieving a compound annual growth rate (CAGR) of 2.77% from FY18 to FY23.
- Profitability - The company has demonstrated reasonable profitability in terms of revenue, primarily due to investment business. The EBIT margin, which stood at 32.9% in FY18, has climbed to 44.2% in FY23, indicating a CAGR of 6.07%.
- Similarly, the net profit margin has shown an increase from 99.1% in FY18 to 101.9% in FY23, showcasing a CAGR of 0.56% over the period from FY18 to FY23. Notably, a substantial portion of the company's revenue is generated from other operating activities, influencing the overall net profit margin.
- Investment Thesis - In comparison to its industry peers, Sigachi Laboratories appears to be slightly overvalued with a P/E ratio of 24.23x, surpassing the current industry average of 21.03x. Additionally, the company relies significantly on income from non-operational activities, a factor that raises concerns about the long-term sustainability of the business. This reliance on non-operational income may create a less favorable perception of the company among investors, potentially impacting investment decisions
Business Rating
Our Team
Independent Director
